Evidence map›Paper›PMID 24342908›Full record

Trial reportStem cells translational medicine2014

Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience.

Cecilia Götherström, Magnus Westgren, S W Steven Shaw, Eva Aström, Arijit Biswas, Peter H Byers, Citra N Z Mattar, Gail E Graham, Jahan Taslimi, Uwe Ewald and 7 more

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cells translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 197 citations in OpenAlex.

  1. Trial
  2. Current Status of Cellular and Gene-Based Therapies for Congenital Metabolic Disorders: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Fetal gene therapy.Journal of inherited metabolic disease · 2024
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Molecular Biomarkers in Perthes Disease: A Review.Diagnostics (Basel, Switzerland) · 2023
    Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 6 countries.

Cecilia GötherströmDivision of Obstetrics and Gynecology, Center for Hematology and Regenerative Medicine, Department of Women's and Children's Health and Neuro-pediatric Unit, and Hematology Center, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Obstetrics and Gynecology and Division of Medical Genetics, Department of Pediatrics, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan; Experimental Fetal Medicine Group, Department of Obstetrics and Gynecology, and Department of Pediatrics, Yong Loo Lin School of Medicine and National University of Singapore, Singapore; Departments of Pathology and Medicine (Medical Genetics), University of Washington, Seattle, Washington, USA; Department of Genetics, Children's Hospital of Eastern Ontario and Department of Pediatrics, University of Ottawa, Ottawa, Canada; Orthopedic Unit, Uppsala University Hospital, Uppsala, Sweden; Women's and Children's Health, Uppsala University, Uppsala, Sweden; Centre for Clinical Research, University of Queensland, Brisbane, Australia; Department of Reproductive Medicine, Women's and Children's Hospital, Singapore; Cancer and Stem Cell Biology, Duke-National University of Singapore Graduate Medical School, Singapore.
Magnus Westgren
S W Steven Shaw
Eva Aström
Arijit Biswas
Peter H Byers
Citra N Z Mattar
Gail E Graham
Jahan Taslimi
Uwe Ewald
Nicholas M Fisk
Allen E J Yeoh
Ju-Li Lin
Po-Jen Cheng
Mahesh Choolani
Katarina Le Blanc
Jerry K Y Chan
National University of Singapore · SGKarolinska Institutet · SELinkou Chang Gung Memorial Hospital · TWChang Gung University · TWKarolinska University Hospital · SEUniversity of Ottawa · CAUniversity of Queensland · AUUniversity of Washington Medical Center · USUppsala University · SEUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteogenesis imperfecta (OI) can be recognized prenatally with ultrasound. Transplantation of mesenchymal stem cells (MSCs) has the potential to ameliorate skeletal damage. We report the clinical course of two patients with OI who received prenatal human fetal MSC (hfMSC) transplantation and postnatal boosting with same-donor MSCs. We have previously reported on prenatal transplantation for OI type III. This patient was retransplanted with 2.8 × 10(6) same-donor MSCs per kilogram at 8 years of age, resulting in low-level engraftment in bone and improved linear growth, mobility, and fracture incidence. An infant with an identical mutation who did not receive MSC therapy succumbed at 5 months despite postnatal bisphosphonate therapy. A second fetus with OI type IV was also transplanted with 30 × 10(6) hfMSCs per kilogram at 31 weeks of gestation and did not suffer any new fractures for the remainder of the pregnancy or during infancy. The patient followed her normal growth velocity until 13 months of age, at which time longitudinal length plateaued. A postnatal infusion of 10 × 10(6) MSCs per kilogram from the same donor was performed at 19 months of age, resulting in resumption of her growth trajectory. Neither patient demonstrated alloreactivity toward the donor hfMSCs or manifested any evidence of toxicities after transplantation. Our findings suggest that prenatal transplantation of allogeneic hfMSCs in OI appears safe and is of likely clinical benefit and that retransplantation with same-donor cells is feasible. However, the limited experience to date means that it is not possible to be conclusive and that further studies are required.

Indexed as

Bone DevelopmentEmbryonic Stem CellsFemaleFetal DiseasesFetusGenotypeHumansMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationOsteogenesis ImperfectaPedigreePregnancyRadiographyCell therapyIn utero transplantationMesenchymal stem cellsMesenchymal stromal cellsOsteogenesis imperfectaPrenatal transplantation

Identifiers

PMID24342908
PMCPMC3925052
OpenAlexW2038919465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.